<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515216</url>
  </required_header>
  <id_info>
    <org_study_id>070433</org_study_id>
    <secondary_id>R21CA123881</secondary_id>
    <nct_id>NCT00515216</nct_id>
  </id_info>
  <brief_title>Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors</brief_title>
  <official_title>Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients who have stomach cancer or cancer of the lower part of the
      esophagus that has spread to other organs. There are many different chemotherapy treatments
      for this type of cancer. At the present time, there is no general agreement on the way to
      choose the most beneficial therapy for an individual patient. Patients with different genetic
      backgrounds may respond differently to the same chemotherapy treatments. In this study the
      investigators will use a certain genetic difference in an important gene (thymidylate
      synthase or TS gene) to see whether treating patients who have a particular type of that gene
      will respond better to a standard chemotherapy regimen. The investigators are hoping that by
      treating patients according to their genes, that they may respond to treatment of their
      cancer better and it will help the investigators choose cancer treatments better in the
      future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric and gastroesophageal junction (GEJ) cancers are a leading cause of cancer mortality.
      Despite the development of newer chemotherapies, the response rates and median survival in
      patients with these tumors has remained essentially stagnant. Defining host and
      molecular/biologic tumor characteristics to customize treatment may lead to improved survival
      outcomes. Retrospective studies have identified genetic markers that predict treatment
      outcome. However, there have been no prospective studies in gastric and GEJ cancer evaluating
      the clinical utility of these genetic factors. We hypothesize that genomically based
      treatment will improve the expected response rate in patients with gastric and GEJ cancers.
      We propose a prospective, multi-institutional Phase II clinical trial testing a germline
      polymorphism in the thymidylate synthase (TS) gene, the number of tandem repeats in the TS
      enhancer region (TSER) as a treatment selection marker. The polymorphic variant conferring
      three tandem repeats (TSER*3) has been associated with 5-FU resistance due to high tumor TS
      expression in comparison to the TSER*2 variant (two tandem repeats). The TSER*3 polymorphism
      is common (allelic frequency of 0.5-0.8). In the proposed study, we will prospectively
      genotype patients with gastric and GEJ cancers. Patients who are expected to be 5-FU
      sensitive (carrying a TSER*2 allele) will receive a 5-FU containing regimen (5-FU,
      leucovorin, oxaliplatin). Patients who are expected to be 5-FU resistant (homozygous for
      TSER*3) will not be included in the study. In completing this study, we will determine
      whether treatment selection based on germline TSER polymorphism status improves the response
      rate in patients with metastatic gastric and GEJ tumors. Additional correlative studies are
      proposed to identify confounding factors that may alter the expected outcomes of this
      treatment approach.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>ORR = complete response + partial response
Complete response - disappearance of all target and non-target lesions
Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>4 years</time_frame>
    <description>Progressive disease - at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>DCR - complete response, partial response, and stable disease
Complete response - disappearance of all target and non-target lesions
Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter
Stable disease - neither sufficient shrinkage to qualify for partial response not sufficient increase to qualify for progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Specific Changes That May Alter Treatment Outcomes</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G&gt;C (rs34743033) gene had a partial tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had a partial tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the ERCC1 c.354C&gt;T (rs11615) gene had a partial tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the ERCC2 c.2251A&gt;C (rs13181) gene had a partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the GSTP1 c.313A&gt;G (rs1695) gene had a partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the XRCC1 c.1196G&gt;A (rs25487) gene had a partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the MDR1 c.3435C&gt;T (rs1045642) gene had a partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G&gt;C (rs34743033) gene had stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the ERCC1 c.354C&gt;T (rs11615) gene had stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the ERCC2 c.2251A&gt;C (rs13181) gene had stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the GSTP1 c.313A&gt;G (rs1695) gene had stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the XRCC1 c.1196G&gt;A (rs25487) gene had stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</measure>
    <time_frame>4 years</time_frame>
    <description>This outcome looks at what genotypes of the MDR1 c.3435C&gt;T (rs1045642) gene had stable disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin/Leucovorin/5-FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Good risk&quot; patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <arm_group_label>Oxaliplatin/Leucovorin/5-FU</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Oxaliplatin/Leucovorin/5-FU</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>Oxaliplatin/Leucovorin/5-FU</arm_group_label>
    <other_name>Wellcovorin</other_name>
    <other_name>citrovorum factor</other_name>
    <other_name>folinic acid</other_name>
    <other_name>5-formyl tetrahydrofolate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed adenocarcinoma of the
             stomach or gastroesophageal junction.

          -  Patients must have measurable disease.

          -  No prior therapy for metastatic disease. Prior neo-adjuvant or adjuvant therapy is
             permitted if the disease free interval has been longer than 6 months.

          -  Age ≥18 years.

          -  Life expectancy of greater than 3 months.

          -  ECOG (Eastern Cooperative Oncology Group) performance status greater than 2 (Karnofsky
             greater than 60%).

          -  Patients must have normal organ and marrow function.

          -  Not pregnant. Not breast feeding.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients may not be receiving any other chemotherapy agents.

          -  Patients with known active brain metastases. Patients with treated brain metastases
             are permitted if stable off steroids for at least 30 days.

          -  History of allergic reactions to 5-FU or oxaliplatin.

          -  Uncontrolled intercurrent illness.

          -  Patients with immune deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert C. Lockhart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Goff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Goldberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Posey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org</url>
    <description>Vanderbilt-Ingram Cancer Center</description>
  </link>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <link>
    <url>http://cancer.med.unc.edu</url>
    <description>UNC Lineberger Comprehensive Cancer Center</description>
  </link>
  <link>
    <url>http://www3.ccc.uab.edu</url>
    <description>University of Alabama at Birmingham . Comprehensive Cancer Center</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2007</study_first_submitted>
  <study_first_submitted_qc>August 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2007</study_first_posted>
  <results_first_submitted>February 11, 2015</results_first_submitted>
  <results_first_submitted_qc>February 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2015</results_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Craig Lockhart</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Phase II</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastroesophageal cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>Thymidylate synthase</keyword>
  <keyword>Pharmacogenomic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Tetrahydrofolates</mesh_term>
    <mesh_term>Formyltetrahydrofolates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study opened to participant enrollment in June 2008 and closed to participant enrollment in October 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxaliplatin/Leucovorin/5-FU</title>
          <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype
Chemotherapy: 5-FU, leucovorin and oxaliplatin (FOLFOX)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxaliplatin/Leucovorin/5-FU</title>
          <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="26" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TSER genotypes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>TSER*2/*2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSER*2/*3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>0 Fully active, able to carry on all pre-disease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
Dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary tumor type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gastric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroesophageal junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incidence of prior neoadjuvant or adjuvant therapy (&gt;6 months)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR = complete response + partial response
Complete response - disappearance of all target and non-target lesions
Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR = complete response + partial response
Complete response - disappearance of all target and non-target lesions
Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="22.2" upper_limit="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="6.3" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progressive disease - at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progressive disease - at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="5.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>DCR - complete response, partial response, and stable disease
Complete response - disappearance of all target and non-target lesions
Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter
Stable disease - neither sufficient shrinkage to qualify for partial response not sufficient increase to qualify for progressive disease</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>DCR - complete response, partial response, and stable disease
Complete response - disappearance of all target and non-target lesions
Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter
Stable disease - neither sufficient shrinkage to qualify for partial response not sufficient increase to qualify for progressive disease</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="79.0" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Specific Changes That May Alter Treatment Outcomes</title>
        <time_frame>4 years</time_frame>
        <population>This was not completed as the archived tumor samples were not of sufficient quality for DNA extraction or analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype
Chemotherapy: 5-FU, leucovorin and oxaliplatin (FOLFOX)</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Specific Changes That May Alter Treatment Outcomes</title>
          <population>This was not completed as the archived tumor samples were not of sufficient quality for DNA extraction or analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
        <description>This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G&gt;C (rs34743033) gene had a partial tumor response.</description>
        <time_frame>4 years</time_frame>
        <population>9 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
          <description>This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G&gt;C (rs34743033) gene had a partial tumor response.</description>
          <population>9 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TYMS, TSER*2/*2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TYMS, TSER*2/*3 (G)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TYMS, TSER*2/*3 (C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
        <description>This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had a partial tumor response.</description>
        <time_frame>4 years</time_frame>
        <population>9 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
          <description>This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had a partial tumor response.</description>
          <population>9 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>+6 bp/+6 bp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+6 bp/-6 bp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
        <description>This outcome looks at what genotypes of the ERCC1 c.354C&gt;T (rs11615) gene had a partial tumor response.</description>
        <time_frame>4 years</time_frame>
        <population>9 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
          <description>This outcome looks at what genotypes of the ERCC1 c.354C&gt;T (rs11615) gene had a partial tumor response.</description>
          <population>9 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
        <description>This outcome looks at what genotypes of the ERCC2 c.2251A&gt;C (rs13181) gene had a partial response.</description>
        <time_frame>4 years</time_frame>
        <population>9 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
          <description>This outcome looks at what genotypes of the ERCC2 c.2251A&gt;C (rs13181) gene had a partial response.</description>
          <population>9 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
        <description>This outcome looks at what genotypes of the GSTP1 c.313A&gt;G (rs1695) gene had a partial response.</description>
        <time_frame>4 years</time_frame>
        <population>9 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
          <description>This outcome looks at what genotypes of the GSTP1 c.313A&gt;G (rs1695) gene had a partial response.</description>
          <population>9 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
        <description>This outcome looks at what genotypes of the XRCC1 c.1196G&gt;A (rs25487) gene had a partial response.</description>
        <time_frame>4 years</time_frame>
        <population>9 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
          <description>This outcome looks at what genotypes of the XRCC1 c.1196G&gt;A (rs25487) gene had a partial response.</description>
          <population>9 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
        <description>This outcome looks at what genotypes of the MDR1 c.3435C&gt;T (rs1045642) gene had a partial response.</description>
        <time_frame>4 years</time_frame>
        <population>9 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response)</title>
          <description>This outcome looks at what genotypes of the MDR1 c.3435C&gt;T (rs1045642) gene had a partial response.</description>
          <population>9 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
        <description>This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G&gt;C (rs34743033) gene had stable disease.</description>
        <time_frame>4 years</time_frame>
        <population>11 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
          <description>This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G&gt;C (rs34743033) gene had stable disease.</description>
          <population>11 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TYMS, TSER*2/*2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TYMS, TSER*2/*3 (G)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TYMS, TSER*2/*3 (C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
        <description>This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had stable disease.</description>
        <time_frame>4 years</time_frame>
        <population>11 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
          <description>This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had stable disease.</description>
          <population>11 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>+6 bp/+6 bp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+6 bp/-6 bp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
        <description>This outcome looks at what genotypes of the ERCC1 c.354C&gt;T (rs11615) gene had stable disease.</description>
        <time_frame>4 years</time_frame>
        <population>11 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
          <description>This outcome looks at what genotypes of the ERCC1 c.354C&gt;T (rs11615) gene had stable disease.</description>
          <population>11 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
        <description>This outcome looks at what genotypes of the ERCC2 c.2251A&gt;C (rs13181) gene had stable disease.</description>
        <time_frame>4 years</time_frame>
        <population>11 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
          <description>This outcome looks at what genotypes of the ERCC2 c.2251A&gt;C (rs13181) gene had stable disease.</description>
          <population>11 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
        <description>This outcome looks at what genotypes of the GSTP1 c.313A&gt;G (rs1695) gene had stable disease.</description>
        <time_frame>4 years</time_frame>
        <population>11 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
          <description>This outcome looks at what genotypes of the GSTP1 c.313A&gt;G (rs1695) gene had stable disease.</description>
          <population>11 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
        <description>This outcome looks at what genotypes of the XRCC1 c.1196G&gt;A (rs25487) gene had stable disease.</description>
        <time_frame>4 years</time_frame>
        <population>11 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
          <description>This outcome looks at what genotypes of the XRCC1 c.1196G&gt;A (rs25487) gene had stable disease.</description>
          <population>11 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G/G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
        <description>This outcome looks at what genotypes of the MDR1 c.3435C&gt;T (rs1045642) gene had stable disease.</description>
        <time_frame>4 years</time_frame>
        <population>11 out of 25 participants had a partial response.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin/Leucovorin/5-FU</title>
            <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)</title>
          <description>This outcome looks at what genotypes of the MDR1 c.3435C&gt;T (rs1045642) gene had stable disease.</description>
          <population>11 out of 25 participants had a partial response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oxaliplatin/Leucovorin/5-FU</title>
          <description>“Good risk” patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>A. Craig Lockhart, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-5740</phone>
      <email>alockhar@dom.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

